LA JOLLA, Calif., July 8 /PRNewswire/ -- La Jolla Diagnostics, Inc. (OTC Bulletin Board: LAJD - news) announced today that it has signed an exclusive agreement with AmTech Scientific, Inc. for sales and distribution of its nutraceutical and consumer health care products in Europe. As part of that agreement, AmTech Scientific has placed a $200,000 initial purchase order, which is expected to be filled over the course of the next 90 days.
''We are extremely enthusiastic about the opportunity to market all of La Jolla Diagnostics' products in Europe,'' said Dr. Stephen Roberts, President of AmTech Scientific. ''While domestic interest in nutraceuticals is growing rapidly, sales in Europe still far exceed those in the U.S. The nutraceutical market in Germany alone exceeds $7 billion annually. We expect La Jolla Diagnostics' proprietary and expanding line of products, especially the current feverfew products, and a new line of allergy products to be very well received throughout Europe.''
La Jolla Diagnostics Products to be distributed include:
Feverfew Nasal Mist(TM). A patent pending moisturizing nasal spray containing the herb feverfew. MigraSpray(TM). A saline solution containing the herb feverfew (commonly used as a treatment for migraine headaches) which is designed to be sprayed under the tongue. Living Water Eye Lotion(TM). A specially formulated saline solution which cleanses and soothes irritated eyes.
Each of the above products is prepared using patented* technology to form ClusterWater(TM). Clustered water is chemically identical with unprocessed water, except that in ClusterWater, polywater complexes enhance the effectiveness of biological solutions. (*U.S. Patent 5711950)
La Jolla Diagnostics is engaged in the development, manufacture, and marketing of diagnostic tests, drug delivery systems, and consumer health care products. |
